Literature DB >> 19083106

Past medical conditions and K-ras mutations in pancreatic ductal adenocarcinoma: a hypothesis-generating study.

Marta Crous-Bou1, Miquel Porta, Eva Morales, Tomàs López, Alfredo Carrato, Elisa Puigdomènech, Francisco X Real.   

Abstract

BACKGROUND: In pancreatic ductal adenocarcinoma (PDA) evidence on the etiopathogenic role of past medical conditions in the occurrence and persistence of K-ras mutations is scant.
METHODS: Incident cases of PDA were interviewed face-to-face about past medical history and other factors. Logistic regression was used to compare PDA cases (n = 120) with wild-type and mutated K-ras tumors (case-case study).
RESULTS: Patients with wild-type K-ras tumors were more likely to have a prior diagnosis of pancreatitis (Odds ratio [OR] = 6.11, p = 0.041). Diabetes mellitus (DM) was non-significantly more common among cases with a K-ras wild-type tumor, and the OR for DM of >6 years of duration was 4.54 (p = 0.39). Patients with wild-type K-ras were significantly more likely to have had a surgically treated peptic ulcer (OR = 9.03, p = 0.027). The probability of having a K-ras wild-type tumor increased with the number of medical conditions (p for trend = 0.012); the corresponding OR for two or more medical conditions was 4.46 (95% CI: 1.37-14.50).
CONCLUSIONS: Results raise the hypothesis that pancreatitis and possibly peptic ulcer might influence pancreatic carcinogenesis through pathways independent of K-ras mutation, perhaps related to growth factors or mediators of the inflammatory response. Large unselected studies should be conducted to refute or replicate our findings.

Entities:  

Mesh:

Year:  2008        PMID: 19083106     DOI: 10.1007/s10552-008-9267-x

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  3 in total

1.  Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients.

Authors:  Lucy A Parker; Miquel Porta; Blanca Lumbreras; Tomàs López; Luisa Guarner; Ildefonso Hernández-Aguado; Alfredo Carrato; Josep M Corominas; Juli Rifà; Esteve Fernandez; Joan Alguacil; Núria Malats; Francisco X Real
Journal:  Eur J Epidemiol       Date:  2011-02-06       Impact factor: 8.082

2.  Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma.

Authors:  Álvaro Gómez-Tomás; José Pumarega; Juan Alguacil; André F S Amaral; Núria Malats; Natàlia Pallarès; Magda Gasull; Miquel Porta
Journal:  Environ Mol Mutagen       Date:  2019-05-23       Impact factor: 3.216

3.  Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

Authors:  P C Butler; A V Matveyenko; S Dry; A Bhushan; R Elashoff
Journal:  Diabetologia       Date:  2009-11-06       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.